Resverlogix Begins Trial of RVX-208

Canadian drugmaker Resverlogix has received FDA approval to begin a Phase Ia trial of RVX-208, a treatment of cardiovascular diseases.

The Phase I trial will consist of three arms —  an ascending single dose, a fed-and-fasted dose effect study and a seven-day ascending multiple dose. The primary objective of the trial is to evaluate the drug in healthy adults for safety, tolerability and pharmacokinetics.

Results for the trial will be used for optimizing dosing for subsequent trials, Resverlogix said.